{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T04:23:07Z","timestamp":1787372587315,"version":"build-2736575974"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T00:00:00Z","timestamp":1787356800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T00:00:00Z","timestamp":1787356800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"GSK","award":["219507"],"award-info":[{"award-number":["219507"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"DOI":"10.1007\/s12325-026-03692-3","type":"journal-article","created":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T03:25:29Z","timestamp":1787369129000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical Remission is Achievable for Adult Patients with Severe Asthma Receiving Mepolizumab: A European Retrospective Chart Review"],"prefix":"10.1007","author":[{"given":"Stephen G.","family":"Noorduyn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha N.","family":"Valliant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Gould","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise H.","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rose","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan","family":"Pinaire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leili","family":"Young-Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei S.","family":"Duh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Aliberti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,22]]},"reference":[{"key":"3692_CR1","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1016\/j.anai.2023.08.609","volume":"131","author":"M Blaiss","year":"2023","unstructured":"Blaiss M, Oppenheimer J, Corbett M, et al. Consensus of an American College of Allergy, Asthma, and Immunology, American Academy of Allergy, Asthma, and Immunology, and American Thoracic Society workgroup on definition of clinical remission in asthma on treatment. Ann Allergy Asthma Immunol. 2023;131:782\u20135.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"3692_CR2","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1016\/j.jaip.2020.10.035","volume":"9","author":"A Menzies-Gow","year":"2021","unstructured":"Menzies-Gow A, Szefler SJ, Busse WW. The relationship of asthma biologics to remission for asthma. J Allergy Clin Immunol Pract. 2021;9:1090\u20138.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"3692_CR3","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/j.jaci.2019.12.006","volume":"145","author":"A Menzies-Gow","year":"2020","unstructured":"Menzies-Gow A, Bafadhel M, Busse WW, et al. An expert consensus framework for asthma remission as a treatment goal. J Allergy Clin Immunol. 2020;145:757\u201365.","journal-title":"J Allergy Clin Immunol"},{"key":"3692_CR4","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1016\/j.jaip.2024.01.044","volume":"12","author":"WW Busse","year":"2024","unstructured":"Busse WW, Chupp G, Corbridge T, Stach-Klysh A, Oppenheimer J. Targeting asthma remission as the next therapeutic step toward improving disease control. J Allergy Clin Immunol Pract. 2024;12:894\u2013903.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"3692_CR5","doi-asserted-by":"publisher","first-page":"3629","DOI":"10.1016\/j.jaip.2023.07.041","volume":"11","author":"GW Canonica","year":"2023","unstructured":"Canonica GW, Blasi F, Carpagnano GE, et al. Severe asthma network italy definition of clinical remission in severe asthma: a delphi consensus. J Allergy Clin Immunol Pract. 2023;11:3629\u201337.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"3692_CR6","unstructured":"Global Initiative for Asthma. Global strategy for asthma management and prevention. 2024. https:\/\/ginasthma.org\/wp-content\/uploads\/2024\/05\/GINA-2024-Strategy-Report-24_05_22_WMS.pdf. Accessed 17 Dec 2025."},{"key":"3692_CR7","unstructured":"European Medicines Agency. NUCALA (mepolizumab) Summary of product characteristics. 2024. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/nucala-epar-product-information_en.pdf. Accessed 17 Dec 2025."},{"key":"3692_CR8","first-page":"106","volume":"9","author":"L Fala","year":"2016","unstructured":"Fala L. Nucala (mepolizumab): first IL-5 antagonist monoclonal antibody FDA approved for maintenance treatment of patients with severe asthma. Am Health Drug Benefits. 2016;9:106\u201310.","journal-title":"Am Health Drug Benefits"},{"key":"3692_CR9","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1016\/j.jaci.2017.10.005","volume":"140","author":"SW Yancey","year":"2017","unstructured":"Yancey SW, Keene ON, Albers FC, et al. Biomarkers for severe eosinophilic asthma. J Allergy Clin Immunol. 2017;140:1509\u201318.","journal-title":"J Allergy Clin Immunol"},{"key":"3692_CR10","doi-asserted-by":"publisher","first-page":"1514","DOI":"10.3389\/fphys.2019.01514","volume":"10","author":"C Pelaia","year":"2019","unstructured":"Pelaia C, Paoletti G, Puggioni F, et al. Interleukin-5 in the pathophysiology of severe asthma. Front Physiol. 2019;10:1514.","journal-title":"Front Physiol"},{"key":"3692_CR11","doi-asserted-by":"publisher","first-page":"2662","DOI":"10.1111\/all.16303","volume":"79","author":"KM Buchheit","year":"2024","unstructured":"Buchheit KM, Shaw D, Chupp G, et al. Interleukin-5 as a pleiotropic cytokine orchestrating airway type 2 inflammation: effects on and beyond eosinophils. Allergy. 2024;79:2662\u201379.","journal-title":"Allergy"},{"key":"3692_CR12","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1056\/NEJMoa1403291","volume":"371","author":"EH Bel","year":"2014","unstructured":"Bel EH, Wenzel SE, Thompson PJ, et al. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N Engl J Med. 2014;371:1189\u201397.","journal-title":"N Engl J Med"},{"key":"3692_CR13","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1056\/NEJMoa1403290","volume":"371","author":"HG Ortega","year":"2014","unstructured":"Ortega HG, Liu MC, Pavord ID, et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med. 2014;371:1198\u2013207.","journal-title":"N Engl J Med"},{"key":"3692_CR14","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1016\/S2213-2600(17)30125-X","volume":"5","author":"GL Chupp","year":"2017","unstructured":"Chupp GL, Bradford ES, Albers FC, et al. Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial. Lancet Respir Med. 2017;5:390\u2013400.","journal-title":"Lancet Respir Med"},{"key":"3692_CR15","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1016\/S0140-6736(12)60988-X","volume":"380","author":"ID Pavord","year":"2012","unstructured":"Pavord ID, Korn S, Howarth P, et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet. 2012;380:651\u20139.","journal-title":"Lancet"},{"key":"3692_CR16","doi-asserted-by":"publisher","first-page":"77","DOI":"10.2147\/JAA.S236609","volume":"13","author":"JP Llanos","year":"2020","unstructured":"Llanos JP, Ortega H, Bogart M, et al. Real-world effectiveness of mepolizumab in patients with severe asthma: an examination of exacerbations and costs. J Asthma Allergy. 2020;13:77\u201387.","journal-title":"J Asthma Allergy"},{"key":"3692_CR17","doi-asserted-by":"publisher","first-page":"689","DOI":"10.2147\/JAA.S275944","volume":"13","author":"J Silver","year":"2020","unstructured":"Silver J, Bogart M, Packnett E, Wu J, McMorrow D, Hahn B. Real-world reductions in oral corticosteroid use in the USA following mepolizumab therapy for severe asthma. J Asthma Allergy. 2020;13:689\u201399.","journal-title":"J Asthma Allergy"},{"key":"3692_CR18","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1007\/s40265-021-01597-9","volume":"81","author":"C Domingo Ribas","year":"2021","unstructured":"Domingo Ribas C, Carrillo Diaz T, Blanco Aparicio M, et al. REal worlD Effectiveness and Safety of mepolizumab in a multicentric spanish cohort of asthma patients stratified by eosinophils: the REDES study. Drugs. 2021;81:1763\u201374.","journal-title":"Drugs"},{"issue":"354\u201362","key":"3692_CR19","volume":"127","author":"T Casale","year":"2021","unstructured":"Casale T, Molfino NA, Silver J, et al. Real-world effectiveness of mepolizumab in patients with severe asthma and associated comorbidities. Ann Allergy Asthma Immunol. 2021;127(354\u201362):e2.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"3692_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.chpulm.2024.100107","volume":"3","author":"C Caruso","year":"2025","unstructured":"Caruso C, Canonica GW, Patel M, et al. Prospective REALITI-A study: 2-year real-world benefits of mepolizumab in severe asthma. CHEST Pulmonary. 2025;3:100107.","journal-title":"CHEST Pulmonary"},{"key":"3692_CR21","doi-asserted-by":"publisher","first-page":"AB233","DOI":"10.1016\/j.jaci.2024.12.717","volume":"155","author":"M Liu","year":"2025","unstructured":"Liu M, Lee J, Gould S, et al. Mepolizumab improves and sustains clinical benefits in patients with severe asthma, independent of blood eosinophil count at baseline: real-world analysis of REALITI-A results at 2 years. J Allergy Clin Immunol. 2025;155:AB233.","journal-title":"J Allergy Clin Immunol"},{"key":"3692_CR22","doi-asserted-by":"publisher","first-page":"1150162","DOI":"10.3389\/fimmu.2023.1150162","volume":"14","author":"I Pavord","year":"2023","unstructured":"Pavord I, Gardiner F, Heaney LG, et al. Remission outcomes in severe eosinophilic asthma with mepolizumab therapy: Analysis of the REDES study. Front Immunol. 2023;14:1150162.","journal-title":"Front Immunol"},{"key":"3692_CR23","doi-asserted-by":"publisher","first-page":"960","DOI":"10.3390\/biomedicines12050960","volume":"12","author":"D Bagnasco","year":"2024","unstructured":"Bagnasco D, Bondi B, Caminati M, et al. Evaluation of clinical remission in best-performing severe asthmatic patients treated for three years with mepolizumab. Biomedicines. 2024;12:960.","journal-title":"Biomedicines"},{"key":"3692_CR24","doi-asserted-by":"publisher","DOI":"10.1080\/02770903.2024.2441887","author":"J Correa-Borit","year":"2024","unstructured":"Correa-Borit J, Laorden D, Arnalich Montiel V, Quirce S, Dominguez-Ortega J. Is it possible to achieve remission in severe asthma? Retrospective analysis of a four-year response in a real-life cohort treated with mepolizumab. J Asthma. 2024. https:\/\/doi.org\/10.1080\/02770903.2024.2441887.","journal-title":"J Asthma"},{"key":"3692_CR25","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1449220","volume":"15","author":"AA Stanziola","year":"2024","unstructured":"Stanziola AA, Candia C, Nazzaro G, et al. Long-term effects of mepolizumab in patients with severe eosinophilic asthma: a 6-year real-life experience. Front Pharmacol. 2024;15:1449220.","journal-title":"Front Pharmacol"},{"key":"3692_CR26","doi-asserted-by":"publisher","first-page":"3315","DOI":"10.1016\/j.jaip.2024.08.033","volume":"12","author":"C Crimi","year":"2024","unstructured":"Crimi C, Nolasco S, Noto A, et al. Long-term clinical and sustained REMIssion in severe eosinophilic asthma treated with mepolizumab: the REMI-M study. J Allergy Clin Immunol Pract. 2024;12:3315\u201327.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"333\u201342","key":"3692_CR27","volume":"13","author":"Y Hamada","year":"2025","unstructured":"Hamada Y, Gibson PG, Harvey ES, et al. Early treatment response to mepolizumab predicts clinical remission in severe eosinophilic asthma. J Allergy Clin Immunol Pract. 2025;13(333\u201342):e9.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"3692_CR28","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1111\/cea.14584","volume":"55","author":"D Di Bona","year":"2025","unstructured":"Di Bona D, Bilancia M, Crimi C, et al. Cluster analysis identifies patients with severe eosinophilic asthma who achieve super-response and remission with mepolizumab. Clin Exp Allergy. 2025;55:202\u20134.","journal-title":"Clin Exp Allergy"},{"key":"3692_CR29","doi-asserted-by":"publisher","first-page":"45","DOI":"10.2500\/aap.2025.46.240084","volume":"46","author":"AI Papaioannou","year":"2025","unstructured":"Papaioannou AI, Kallieri M, Zervas E, et al. Clinical remission in patients with severe eosinophilic asthma treated with mepolizumab: a post-hoc analysis of RELIght study. Allergy Asthma Proc. 2025;46:45\u201351.","journal-title":"Allergy Asthma Proc"},{"key":"3692_CR30","doi-asserted-by":"publisher","first-page":"00211","DOI":"10.1183\/23120541.00211-2024","volume":"11","author":"FJ Gonz\u00e1lez-Barcala","year":"2025","unstructured":"Gonz\u00e1lez-Barcala FJ, Bobolea I, Dom\u00ednguez-Ortega J, et al. Time is lung: higher preservation of lung function in severe asthma patients after earlier mepolizumab treatment. ERJ Open Research. 2025;11:00211\u20132024.","journal-title":"ERJ Open Research"},{"key":"3692_CR31","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/S2213-2600(24)00293-5","volume":"13","author":"A Shackleford","year":"2025","unstructured":"Shackleford A, Heaney LG, Redmond C, McDowell PJ, Busby J. Clinical remission attainment, definitions, and correlates among patients with severe asthma treated with biologics: a systematic review and meta-analysis. Lancet Respir Med. 2025;13:23\u201334.","journal-title":"Lancet Respir Med"},{"key":"3692_CR32","doi-asserted-by":"publisher","first-page":"2300819","DOI":"10.1183\/13993003.00819-2023","volume":"62","author":"PJ McDowell","year":"2023","unstructured":"McDowell PJ, McDowell R, Busby J, et al. Clinical remission in severe asthma with biologic therapy: an analysis from the UK severe asthma registry. Eur Respir J. 2023;62:2300819.","journal-title":"Eur Respir J"},{"key":"3692_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.opresp.2025.100418","volume":"7","author":"L Perez-de Llano","year":"2025","unstructured":"Perez-de Llano L, Bonilla MG, Luzon E, Ramos-Lima F, Miralles JC. What we know to date about early treatment with biologics in severe asthma: a scoping review about the use of biologics in severe asthma and possible parallels with early rheumatoid arthritis. Open Respir Arch. 2025;7:100418.","journal-title":"Open Respir Arch"},{"key":"3692_CR34","doi-asserted-by":"publisher","first-page":"2102583","DOI":"10.1183\/13993003.02583-2021","volume":"60","author":"D Thomas","year":"2022","unstructured":"Thomas D, McDonald VM, Pavord ID, Gibson PG. Asthma remission: what is it and how can it be achieved? Eur Respir J. 2022;60:2102583.","journal-title":"Eur Respir J"},{"key":"3692_CR35","doi-asserted-by":"publisher","DOI":"10.3390\/biologics6010004","volume":"6","author":"T Suzuki","year":"2026","unstructured":"Suzuki T, Tajiri T, Ozawa Y, et al. Clinical remission and its predictors after 12 months of biologic therapy in severe asthma. Biologics. 2026;6:4.","journal-title":"Biologics"},{"key":"3692_CR36","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1164\/rccm.202311-2192OC","volume":"210","author":"L Perez-de-Llano","year":"2024","unstructured":"Perez-de-Llano L, Scelo G, Tran TN, et al. Exploring definitions and predictors of severe asthma clinical remission after biologic treatment in adults. Am J Respir Crit Care Med. 2024;210:869\u201380.","journal-title":"Am J Respir Crit Care Med"},{"key":"3692_CR37","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1111\/all.15867","volume":"79","author":"D Thomas","year":"2024","unstructured":"Thomas D, McDonald VM, Stevens S, et al. Biologics (mepolizumab and omalizumab) induced remission in severe asthma patients. Allergy. 2024;79:384\u201392.","journal-title":"Allergy"},{"key":"3692_CR38","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/S2213-2600(24)00304-7","volume":"13","author":"M Lommatzsch","year":"2025","unstructured":"Lommatzsch M, Virchow JC. Asthma remission: a call for a globally standardised definition. Lancet Respir Med. 2025;13:2\u20133.","journal-title":"Lancet Respir Med"},{"key":"3692_CR39","doi-asserted-by":"publisher","first-page":"2100300","DOI":"10.1183\/13993003.00300-2021","volume":"57","author":"M Masoli","year":"2021","unstructured":"Masoli M, Lanario JW, Hyland ME, et al. The severe asthma questionnaire: sensitivity to change and minimal clinically important difference. Eur Respir J. 2021;57:2100300.","journal-title":"Eur Respir J"},{"key":"3692_CR40","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/0895-4356(94)90036-1","volume":"47","author":"EF Juniper","year":"1994","unstructured":"Juniper EF, Guyatt GH, Willan A, Griffith LE. Determining a minimal important change in a disease-specific quality of life questionnaire. J Clin Epidemiol. 1994;47:81\u20137.","journal-title":"J Clin Epidemiol"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03692-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-026-03692-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03692-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T03:25:32Z","timestamp":1787369132000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-026-03692-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,22]]},"references-count":40,"alternative-id":["3692"],"URL":"https:\/\/doi.org\/10.1007\/s12325-026-03692-3","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,22]]},"assertion":[{"value":"31 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Stephen G. Noorduyn and Steven Gould are employed by GSK and hold financial equities in GSK. Samantha N. Valliant was a university worker employed by GSK at the time of the study; she is currently employed by Daiichi Sankyo. Louise H. Yu, Rose Chang, Megan Pinaire, Leili Young-Xu, and Mei S. Duh are employees of Analysis Group, Inc., which received payment from GSK to conduct this study. Rui Song was employed by Analysis Group, Inc. at the time of the study; they are currently employed by Bayer. Stefano Aliberti has received consultancy or speaker fees from GSK, unrelated to this study.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted in accordance with applicable laws regarding participant privacy. No direct patient contact or primary collection of individual human data occurred, and all data were anonymised; therefore, informed consent was not required. The study received an exemption from Pearl institutional review board and was registered with the Paul-Ehrlich Institute in Germany.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}